[(18)F]FMISO and [(18)F]FDG PET imaging in soft tissue sarcomas: correlation of hypoxia, metabolism and VEGF expression
- PMID: 12632200
- DOI: 10.1007/s00259-002-1096-7
[(18)F]FMISO and [(18)F]FDG PET imaging in soft tissue sarcomas: correlation of hypoxia, metabolism and VEGF expression
Abstract
Hypoxia imparts resistance to radiotherapy and chemotherapy and also promotes a variety of changes in tumor biology through inducible promoters. The purpose of this study was to evaluate the use of positron emission tomography (PET) imaging with fluorine-18 fluoromisonidazole (FMISO) in soft tissue sarcomas (STS) as a measure of hypoxia and to compare the results with those obtained using [(18)F]fluorodeoxyglucose (FDG) and other known biologic correlates. FDG evaluates energy metabolism in tumors while FMISO uptake is proportional to tissue hypoxia. FMISO uptake was compared with FDG uptake. Vascular endothelial growth factor (VEGF) expression was also compared with FMISO uptake. Nineteen patients with STS underwent PET scanning with quantitative determination of FMISO and FDG uptake prior to therapy (neo-adjuvant chemotherapy or surgery alone). Ten patients receiving neo-adjuvant chemotherapy were also imaged after chemotherapy but prior to surgical resection. Standardized uptake value (SUV) was used to describe FDG uptake; regional tissue to blood ratio (>or=1.2 was considered significant) was used for FMISO uptake. Significant hypoxia was found in 76% of tumors imaged prior to therapy. No correlation was identified between pretherapy hypoxic volume (HV) and tumor grade ( r=0.15) or tumor volume ( r=0.03). The correlation of HV with VEGF expression was 0.39. Individual tumors showed marked heterogeneity in regional VEGF expression. The mean pixel-by-pixel correlation between FMISO and FDG uptake was 0.49 (range 0.09-0.79) pretreatment and 0.32 (range -0.46-0.72) after treatment. Most tumors showed evidence of reduced uptake of both FMISO and FDG following chemotherapy. FMISO PET demonstrates areas of significant and heterogeneous hypoxia in soft tissue sarcomas. The significant discrepancy between FDG and FMISO uptake seen in this study indicates that regional hypoxia and glucose metabolism do not always correlate. Similarly, we did not find any relationship between the hypoxic volume and the tumor volume or VEGF expression. Identification of hypoxia and development of a more complete biologic profile of STS will serve to guide more rational, individualized cancer treatment approaches.
Similar articles
-
Lack of correlation of hypoxic cell fraction and angiogenesis with glucose metabolic rate in non-small cell lung cancer assessed by 18F-Fluoromisonidazole and 18F-FDG PET.J Nucl Med. 2006 Dec;47(12):1921-6. J Nucl Med. 2006. PMID: 17138734
-
Positron emission tomography/computed tomography imaging of residual skull base chordoma before radiotherapy using fluoromisonidazole and fluorodeoxyglucose: potential consequences for dose painting.Int J Radiat Oncol Biol Phys. 2012 Nov 1;84(3):681-7. doi: 10.1016/j.ijrobp.2011.12.047. Epub 2012 Mar 3. Int J Radiat Oncol Biol Phys. 2012. PMID: 22391104 Clinical Trial.
-
The reoxygenation of hypoxia and the reduction of glucose metabolism in head and neck cancer by fractionated radiotherapy with intensity-modulated radiation therapy.Eur J Nucl Med Mol Imaging. 2016 Nov;43(12):2147-2154. doi: 10.1007/s00259-016-3431-4. Epub 2016 Jun 1. Eur J Nucl Med Mol Imaging. 2016. PMID: 27251644 Clinical Trial.
-
From tumor biology to clinical Pet: a review of positron emission tomography (PET) in oncology.Ann Nucl Med. 2001 Dec;15(6):471-86. doi: 10.1007/BF02988499. Ann Nucl Med. 2001. PMID: 11831394 Review.
-
Role of Non-FDG-PET/CT in Head and Neck Cancer.Semin Nucl Med. 2021 Jan;51(1):68-78. doi: 10.1053/j.semnuclmed.2020.07.008. Epub 2020 Aug 7. Semin Nucl Med. 2021. PMID: 33246541 Review.
Cited by
-
Functionalized Ultrasmall Iron Oxide Nanoparticles for T1-Weighted Magnetic Resonance Imaging of Tumor Hypoxia.Molecules. 2022 Oct 15;27(20):6929. doi: 10.3390/molecules27206929. Molecules. 2022. PMID: 36296522 Free PMC article.
-
Imaging radiation response in tumor and normal tissue.Am J Nucl Med Mol Imaging. 2015 Jun 15;5(4):317-32. eCollection 2015. Am J Nucl Med Mol Imaging. 2015. PMID: 26269771 Free PMC article. Review.
-
Multi-tracer small animal PET imaging of the tumour response to the novel pan-Erb-B inhibitor CI-1033.Eur J Nucl Med Mol Imaging. 2006 Apr;33(4):441-52. doi: 10.1007/s00259-005-0039-5. Epub 2006 Feb 1. Eur J Nucl Med Mol Imaging. 2006. PMID: 16450138
-
PET radiopharmaceuticals for imaging of tumor hypoxia: a review of the evidence.Am J Nucl Med Mol Imaging. 2014 Jun 7;4(4):365-84. eCollection 2014. Am J Nucl Med Mol Imaging. 2014. PMID: 24982822 Free PMC article. Review.
-
Development of a nomogram combining clinical staging with (18)F-FDG PET/CT image features in non-small-cell lung cancer stage I-III.Eur J Nucl Med Mol Imaging. 2016 Jul;43(8):1477-85. doi: 10.1007/s00259-016-3325-5. Epub 2016 Feb 20. Eur J Nucl Med Mol Imaging. 2016. PMID: 26896298 Free PMC article.
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical